Michael G Agadjanyan

Institute for Molecular Medicine

NIH Rank #1604
  • Program Leader
  • R01 Holder
  • Top 10% Funded
  • Early Career

NIH Funding · FY2024

Total Funding
$4M
Fiscal year 2024
Grants Awarded
2
Active NIH grants
National Rank
#1,604
Among 57,894 PIs
First NIH Award
2024
Year of first funding

Funding & rank history

NIH funding totals and national rank by fiscal year.

Single fiscal year on record (FY2024): $4M across 2 grants · National rank #1604.

Top grants by award amount

Michael G Agadjanyan's NIH grant portfolio, ranked by award amount.

  • 5R01AG074983-03R01
    Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
    $2.2M
    award amount
  • 1U01AG084528-01U01
    IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)
    $1.8M
    award amount

Affiliation

Institutions that have administered grants for Michael G Agadjanyan.

Affiliated with Institute for Molecular Medicine (CA).

Career milestones

Key NIH funding milestones over time.

  1. 2024
    First NIH Award
    Institute for Molecular Medicine
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    Entered Top 50% Nationally
    Ranked #1604
  6. 2024
    Entered Top 25% Nationally
    Ranked #1604
  7. 2024
    Entered Top 10% Nationally
    Ranked #1604

Related investigators

Other NIH-funded PIs frequently associated with Michael G Agadjanyan.